Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
BioVie Inc banner

BioVie Inc
NASDAQ:BIVI

Watchlist Manager
BioVie Inc Logo
BioVie Inc
NASDAQ:BIVI
Watchlist
Price: 1.11 USD 4.72% Market Closed
Market Cap: $8.4m
Write Note Create Alert Ask AI

Net Margin

0%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Net
Margin
US
BioVie Inc
NASDAQ:BIVI
8.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.1B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
204.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
190B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Other Profitability Ratios

BioVie Inc
Glance View

Market Cap
8.4m USD
Industry
Biotechnology

BioVie, Inc. is a biopharmaceutical company, which discovers, develops and commercializes drug therapies for liver disease. The company is headquartered in Santa Monica, California. The company went IPO on 2014-01-14. The firm is focused on developing and commercializing BIV201 (continuous infusion terlipressin) an approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The firm is developing BIV201, a treatment option for patients suffering from ascites and other life-threatening complications of advanced liver cirrhosis caused by hepatitis, nonalcoholic steatohepatitis (NASH) and alcoholism. The firm is also engaged in developing NE3107, an ERK inhibitor that selectively reduces neuroinflammation and insulin resistance.

BIVI Intrinsic Value
Not Available
What is Intrinsic Value?

See Also

Summary
BIVI intrinsic value, competitors valuation, and company profile.
DCF Valuation
BIVI stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BIVI stock valuation using valuation multiples.
Wall Street Estimates
BIVI price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BIVI stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Back to Top
ALPHA SPREAD
Follow us
Join more than 315,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.